STI Testing and Treatment Guide: 2026 Complete Plan

More than 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023 alone — and that number only counts what was diagnosed. This STI testing and treatment guide exists because the gap between infection and awareness remains the single most dangerous feature of sexually transmitted infections. Most people carrying an STI have no symptoms. None. That means the person who feels completely fine can still transmit an infection that, left untreated, causes infertility, organ damage, or — in the case of congenital syphilis — the death of a newborn. Knowing when to test, how to test, and what treatment looks like is not just clinical knowledge. It is preventive power.

The good news is that the overall picture is slowly improving. Provisional CDC STI Surveillance data for 2024 shows a combined 9% decline in chlamydia, gonorrhea, and syphilis cases compared to 2023 — the third consecutive annual decline. But context matters: 2024’s totals are still 13% higher than they were a decade ago, and congenital syphilis cases have surged roughly 700% over that same period. The downward trend is real; the crisis is not over.

This guide covers everything from plain-language definitions of clinical terms to specific drug dosages, screening timelines, and what happens after a positive result. Whether you are reading this because of a potential exposure, a routine checkup question, or simple curiosity about your health, the information here is grounded in CDC 2021 STI Treatment Guidelines and USPSTF recommendations — the same evidence base clinicians use every day.

Plain-Language Glossary: Key Terms Defined Without the Jargon

Clinical language can make a straightforward conversation feel inaccessible. Before moving into screening criteria and treatment protocols, it helps to define the terms that appear throughout every STI conversation. Think of this as a decoder ring for your next provider visit.

• NAAT (Nucleic Acid Amplification Test): A laboratory method that detects the actual DNA or RNA of a pathogen. It is the gold standard for diagnosing chlamydia and gonorrhea. Think of it as searching for the invader’s fingerprint rather than your body’s reaction to it.
• Incubation period: The time between exposure to an infection and the appearance of symptoms. This is different from the window period. For example, gonorrhea symptoms may appear 1–14 days after exposure — but some people never develop symptoms at all.
• Window period: The time between exposure and when a test can reliably detect the infection. Testing too early — before the window closes — can produce a false-negative result even when infection is present.
• Serology: A blood test that detects antibodies your immune system has made in response to an infection. Used for syphilis (RPR/VDRL followed by a treponemal confirmatory test), HIV (4th-generation Ag/Ab combination assay), and herpes (HSV-2 antibody testing).
• Test-of-cure (TOC): A follow-up test performed after treatment to confirm the infection has been eliminated. Not required for every STI, but essential for certain situations — particularly pharyngeal gonorrhea and chlamydia in pregnancy.
• Expedited Partner Therapy (EPT): The practice of providing medication or a prescription to a patient’s sexual partner(s) without requiring the partner to come in for a clinical examination. It is legal in most U.S. states and is recommended by the CDC to reduce reinfection rates.
• PrEP (Pre-Exposure Prophylaxis): A daily antiretroviral medication regimen taken by HIV-negative individuals at high risk for HIV. The USPSTF recommends PrEP for people who have been diagnosed with gonorrhea or syphilis in the prior six months.
• PEP (Post-Exposure Prophylaxis): Anti-HIV medication taken after a potential HIV exposure. Must be started within 72 hours and taken for 28 days.
• Chancre: The painless, firm, round ulcer that marks primary syphilis at the site of infection. It resolves on its own, which is part of why syphilis is so often missed.
• Asymptomatic infection: An active infection that causes no noticeable symptoms. According to data cited by multiple public health agencies, more than 50% of all STI cases are asymptomatic — meaning testing, not symptoms, is the only reliable detection method.

Who Should Get Tested: Risk-Based Screening Criteria

Feeling healthy is not the same as being STI-free. The USPSTF 2021 Recommendation on chlamydia and gonorrhea screening makes this explicit: screening frequency should be triggered by new or persistent risk factors, not by symptoms. For women aged 25 and older, the USPSTF uses a risk-factor approach rather than a fixed annual interval. Here is how to assess your situation:

1. All sexually active women aged 24 and under: Screen for chlamydia and gonorrhea. This is a USPSTF Grade B recommendation, meaning the evidence of benefit is substantial. Infection rates are highest in adolescents and young adults — this age group accounted for approximately 48.2% of all reported chlamydia, gonorrhea, and syphilis cases in 2023.
2. Women aged 25 and older with any of the following risk factors: New sexual partner; more than one sexual partner; a partner with concurrent partners; a partner with an STI; inconsistent condom use outside of a mutually monogamous relationship; a previous or current STI; history of exchanging sex for money or drugs; or history of incarceration.
3. Men who have sex with men (MSM): Annual screening for chlamydia, gonorrhea, and syphilis at all anatomic sites of sexual exposure (urethral, rectal, pharyngeal). Testing every 3–6 months if you are HIV-positive, on PrEP, have multiple partners, or have a prior STI history.
4. All adults and adolescents aged 15–65: At least one lifetime HIV screening test, regardless of risk level, per USPSTF guidance. Annual HIV testing for MSM with more than one partner; every 3–6 months for those at higher risk.
5. Anyone with a known exposure: If a sexual partner informs you of a positive diagnosis, targeted testing for that specific STI — even if you have no symptoms — is the appropriate response. Do not wait for symptoms.
6. Anyone with a prior STI diagnosis: Retest 3 months after completing treatment for chlamydia or trichomoniasis, per CDC guidelines, due to high reinfection rates. More frequent ongoing screening is warranted if risk factors persist.
7. Persons with HIV: Screen for syphilis, gonorrhea, and chlamydia at the initial HIV care visit, then at least annually thereafter.

For men who feel completely fine and have no symptoms, the national guidelines are not sure whether testing every man automatically is the best approach for the general population — not because testing is a bad idea, but because the research has not yet clearly shown it benefits all men equally. This is simply the guidelines saying: “We do not have enough data yet to make a blanket rule here.”What that does NOT mean: skip testing. It means your personal situation matters more than any one-size-fits-all rule. If you have new partners, inconsistent condom use, a previous STI, or anything else that raises your individual risk, talk to your doctor about getting tested. Your doctor is exactly the right person to weigh your specific circumstances — and for many men, testing is absolutely the right call.

Why Asymptomatic Infection Changes Everything

Here is the analogy that clarifies why regular testing matters regardless of how you feel. Imagine a slow gas leak in your home. You smell nothing. The appliances run normally. Life proceeds without alarm — until the accumulation causes a real problem. Asymptomatic STI carriage works the same way. The infection is active, progressing in some cases, and fully transmissible, but the body raises no audible alarm. Chlamydia, for instance, can silently damage fallopian tubes for months, eventually causing infertility or ectopic pregnancy, without a single presenting symptom. Gonorrhea can ascend to the upper reproductive tract, causing pelvic inflammatory disease (PID), under the same conditions. Testing is the functional equivalent of installing a gas detector — it finds the problem before the accumulation becomes catastrophic.

STI-by-STI Breakdown: What You Need to Know About Each Infection

Chlamydia (Chlamydia trachomatis)

Chlamydia remains the most frequently reported bacterial STI in the United States, with 1,648,568 cases reported in 2023. It infects the genital tract, rectum, and throat. Most people — male and female — have no symptoms. When symptoms do appear, they typically develop 7–21 days after exposure and may include discharge, burning with urination, or pelvic discomfort.

The window period for NAAT detection is approximately 1–2 weeks post-exposure. Testing too early can miss an infection that is genuinely present. Untreated chlamydia in people with a uterus can lead to PID, chronic pelvic pain, tubal factor infertility, and ectopic pregnancy. Newborns exposed during delivery risk neonatal chlamydial pneumonia or ophthalmia neonatorum.

Gonorrhea (Neisseria gonorrhoeae)

Gonorrhea reported 601,319 cases in 2023, down 10% in 2024 provisional data. The bacterium infects the urethra, rectum, cervix, and throat — and pharyngeal gonorrhea is particularly concerning because it is often asymptomatic and harder to eradicate. The incubation period is 1–14 days; the NAAT window period is roughly 2–6 days.

Antibiotic resistance is a serious clinical concern. The CDC estimates that approximately half of all gonorrhea infections are resistant to at least one antibiotic. This resistance profile is the reason treatment guidelines changed in 2021 — shifting entirely to injectable ceftriaxone as the first-line therapy, discontinuing oral azithromycin co-treatment for gonorrhea.

Syphilis (Treponema pallidum)

Syphilis progresses through distinct stages: primary (painless chancre at the infection site), secondary (rash, flu-like symptoms), latent (no symptoms, detectable by serology), and tertiary (organ damage, neurological involvement). The incubation period ranges from 10–90 days, with an average of about 21 days. The serological window period is 3–12 weeks.

Primary and secondary syphilis among men declined 24% from 2023 to 2024, per provisional CDC data. However, early non-primary, non-secondary syphilis — an indicator of recent infection not yet fully staged — actually increased among women by nearly 8% in 2024. And congenital syphilis, which infects infants during pregnancy, has surged from a rate of 12.4 per 100,000 live births in 2015 to 102.0 per 100,000 in 2024 — an increase of over 722%. Nearly 4,000 congenital syphilis cases were reported in 2024 alone.

Clinical note on Bicillin L-A shortage: As of March 2026, the FDA authorized the temporary importation of Lentocilin due to a limited availability of Bicillin L-A (benzathine penicillin G), the preferred injectable treatment for syphilis. Providers and patients should consult the CDC STI Treatment Guidelines hub for the most current guidance on drug availability and substitution protocols.

Pelvic Inflammatory Disease (PID)

PID is not a single pathogen — it is an upper genital tract infection, typically caused by ascending chlamydia or gonorrhea from the cervix into the uterus, fallopian tubes, and ovaries. Over a 10-year period, approximately 2 million reproductive-aged women in the U.S. self-reported a PID diagnosis. Symptoms include lower abdominal pain, fever, unusual discharge, and pain with intercourse — though mild or subclinical PID is common and frequently missed. Consequences of untreated PID include infertility, chronic pelvic pain, and ectopic pregnancy.

Non-Gonococcal Urethritis (NGU)

NGU is inflammation of the urethra caused by organisms other than gonorrhea — most commonly Chlamydia trachomatis, but also Mycoplasma genitalium, Ureaplasma, and others. It primarily affects people with a penis and presents with urethral discharge and burning on urination. Because symptoms overlap with gonorrhea, testing is required to distinguish between them. Treatment targets the most likely causative organisms, with doxycycline as the first-line approach per CDC 2021 guidelines.

Cervicitis

Cervicitis is inflammation of the cervix, often caused by chlamydia or gonorrhea but also by herpes or Mycoplasma genitalium. Many cases are asymptomatic; others present with mucopurulent discharge or bleeding. It is clinically significant both as a condition itself and as a marker that ascending infection — potentially leading to PID — may occur if left untreated. Testing should include NAAT for both chlamydia and gonorrhea, with treatment guided by confirmed or suspected organism.

HIV (Human Immunodeficiency Virus)

HIV attacks CD4 cells, progressively weakening immune function if untreated. The 4th-generation HIV-1/2 Antigen/Antibody (Ag/Ab) combination immunoassay is the CDC-recommended initial test — it can detect infection within 18–45 days of exposure. For highest accuracy, the general window period is approximately 23–90 days depending on the test type used; the HIV RNA NAT test detects infection within 10–33 days.

HIV is not curable, but with antiretroviral therapy (ART), people living with HIV can achieve an undetectable viral load — meaning the virus cannot be sexually transmitted to a partner (U=U: Undetectable = Untransmittable). The USPSTF recommends HIV screening for all adults ages 15–65 as a universal standard, and annual or more frequent testing for high-risk groups.

STI Testing Methods Explained: NAAT vs. Serology vs. Culture

Not all STI tests work the same way. The method matters because it determines what the test can detect, how early, and how reliably. Here is how the three primary testing approaches compare:

A practical note on specimen collection: for chlamydia and gonorrhea NAAT, vaginal swabs are the preferred specimen for people with a vagina; first-void urine (the first 20–30 mL of the urine stream) is preferred for people with a penis. Rectal and pharyngeal swabs can be processed with NAAT under CLIA-validated lab protocols, though no commercial NAAT kits are currently FDA-cleared for those sites.

For gonorrhea test-of-cure specifically: culture performed at least 3 days after treatment completion is the preferred method. If culture is unavailable, NAAT is acceptable — but must be performed 3–4 weeks after treatment to avoid false-positives from residual nucleic acid.

STI Testing and Treatment Guide: Full Treatment Protocols by Infection

Treatment for bacterial STIs is curative when completed correctly. Viral STIs are managed, not cured. The table below reflects CDC 2021 STI Treatment Guidelines (Workowski KA, Bachmann LH, Chan PA, et al., MMWR Recomm Rep. 2021;70(4):1–187) — the current evidence standard for U.S. clinical practice.

Curable vs. Managed: Understanding Bacterial and Viral STIs

This distinction matters more than almost any other in this guide. Bacterial STIs — chlamydia, gonorrhea, syphilis, trichomoniasis, PID, and NGU — are curable. Complete the prescribed antibiotic course, confirm resolution through follow-up testing where indicated, and the infection is gone. That is the treatment arc: exposure, diagnosis, treatment, confirmation.

Viral STIs work differently. HPV, herpes (HSV-1 and HSV-2), and HIV are not curable. The virus integrates into the body and remains. But “not curable” is not the same as “unmanageable.” HIV, treated with antiretroviral therapy, can be suppressed to undetectable levels — meaning zero risk of sexual transmission and a near-normal life expectancy. Herpes suppressive therapy with valacyclovir or acyclovir reduces outbreak frequency and transmission risk, though it does not eliminate shedding entirely. HPV presents its own dynamic: most immune-competent individuals clear the virus naturally within 1–2 years, but high-risk strains (particularly HPV 16 and 18) carry oncogenic potential and require ongoing surveillance through cervical screening and, where applicable, the HPV vaccine. The nonavalent vaccine (Gardasil 9) protects against nine HPV strains and is recommended for all individuals through age 26; shared decision-making applies for ages 27–45. Lifelong risk management for viral STIs is not a failure of medicine — it is how medicine currently succeeds with these pathogens.

Follow-Up and Retesting: What Happens After Treatment

Treatment is not the final step. Retesting protocols exist because reinfection is common and test-of-cure requirements vary by organism and clinical situation.

• Chlamydia (general population): Retest 3 months after completing treatment. This is not a test-of-cure (which would confirm treatment worked) — it is a reinfection screen. The CDC recommends this for all chlamydia patients due to high reinfection rates. If NAAT is used for test-of-cure in a clinical situation that warrants it, wait 3–4 weeks post-treatment to avoid false-positives from residual nucleic acid.
• Chlamydia (pregnancy): Test-of-cure using NAAT is recommended 4 weeks after treatment completion, given the consequences of persistent infection during pregnancy.
• Gonorrhea (pharyngeal): Test-of-cure at 14 days post-treatment, using either culture or NAAT. Pharyngeal gonorrhea is harder to clear and resistance is more common at this site.
• Gonorrhea (general): Repeat screening approximately 6 months post-treatment. Immediate test-of-cure by culture is recommended if antimicrobial resistance is suspected or if treatment response is uncertain.
• Trichomoniasis: Retest 3 months after treatment. Reinfection through untreated partners is the primary driver of treatment failure.
• Syphilis: Follow-up serologic testing at 6 and 12 months to confirm adequacy of treatment. Providers look for a fourfold decline in non-treponemal antibody titers (RPR or VDRL). Failure to decline warrants evaluation for reinfection or treatment failure.
• All patients diagnosed with chlamydia, gonorrhea, or trichomonas: Per AAFP and CDC guidance, co-testing for HIV and syphilis is recommended at the time of initial STI diagnosis, as co-infections are common and alter clinical management.

Special Populations: Adolescents and Pregnant Individuals

Adolescents (Ages 15–24)

Adolescents and young adults bear a disproportionate burden of STIs. In 2023, this age group accounted for approximately 48.2% of all reported chlamydia, gonorrhea, and syphilis cases in the U.S. Infection rates for chlamydia and gonorrhea are highest in this group across both sexes. The USPSTF gives annual chlamydia and gonorrhea screening for all sexually active women through age 24 its highest recommendation (Grade B) — meaning the net benefit is substantial and the recommendation applies without exception for behavioral risk factors.

Confidentiality is a significant barrier for adolescent testing. Many states have minor consent laws that allow adolescents to access STI testing and treatment without parental notification. Providers and patients should be aware of their state’s specific provisions. Community health clinics and federally qualified health centers often serve adolescent populations with free or low-cost confidential STI services.

HPV vaccination is particularly time-sensitive in this population. The vaccine is most effective when given before sexual debut. The two-dose series is completed before age 15; three doses are required if the series begins at age 15 or later.

Pregnant Individuals

Pregnancy is a high-stakes context for STI screening because untreated infections harm both the gestating person and the developing fetus. Current recommendations include universal screening for HIV, syphilis, and hepatitis B for all pregnant women — regardless of perceived risk. Chlamydia, gonorrhea, and hepatitis C screening is risk-based.

Pregnant women under 25, or aged 25 and older with risk factors, should be screened for both gonorrhea and chlamydia. Syphilis serologic status must be determined at least once during pregnancy per CDC guidelines; in high-prevalence areas, repeat testing in the third trimester and at delivery is standard. Untreated syphilis during pregnancy caused nearly 4,000 cases of congenital syphilis in 2024 — a preventable tragedy that reflects failures in prenatal care access and screening coverage, not a lack of effective treatment.

Pregnant individuals with trichomoniasis face increased risk of preterm delivery and low birthweight. Treatment with metronidazole is used during pregnancy, with the 7-day regimen now preferred. Herpes suppressive therapy (valacyclovir or acyclovir) is recommended starting at 36 weeks’ gestation to reduce the risk of neonatal herpes transmission during delivery.

Doxycycline — first-line for chlamydia and PID in the general population — is contraindicated after the first trimester of pregnancy due to fetal bone and tooth development effects. Alternative regimens (azithromycin-based) apply in this context; a provider consultation is essential for any STI diagnosis during pregnancy.

Doxycycline PEP: An Emerging Prevention Tool

Doxycycline post-exposure prophylaxis (doxy-PEP) — taking doxycycline 200 mg within 72 hours of condomless sex — has emerged as a meaningful STI prevention strategy for specific high-risk groups. In MSM and transgender women, doxy-PEP reduced incident chlamydia by approximately 70% and syphilis by approximately 73%, though it showed no significant effect on gonorrhea. The CDC now recommends considering doxy-PEP for MSM and transgender women with a history of recent STIs. Part of the 2023–2024 decline in chlamydia and syphilis may reflect the growing uptake of this intervention, according to the CDC’s NCHHSTP.

Frequently Asked Questions

Can I test for STIs at home?

Yes. NAAT-based at-home testing kits are available for chlamydia, gonorrhea, HIV, and other infections. They are a reasonable option for people with privacy concerns or limited clinic access. However, at-home testing has limitations: sample quality depends on user technique, and a positive result from a home kit should always be confirmed by a clinical provider who can prescribe treatment, conduct contact tracing, and evaluate for co-infections.

If I have no symptoms, do I actually need to test?

Yes. More than 50% of all STIs produce no symptoms. Chlamydia and gonorrhea can silently damage reproductive organs for months. Syphilis’s primary chancre heals on its own, creating the illusion of resolution while the infection progresses to the secondary stage. The absence of symptoms is not evidence of the absence of infection.

What does a positive result actually mean?

A positive NAAT for chlamydia or gonorrhea means the pathogen’s genetic material was detected in your sample — the infection is present and treatable. A reactive syphilis serology (RPR) means antibodies to syphilis have been detected; a confirmatory treponemal test is needed to rule out false positives and stage the infection. A positive HIV test requires confirmatory differentiation testing. In every case, a positive result means contact your provider promptly — and inform your recent sexual partners, either directly or through your health department’s anonymous partner notification services.

Does treating an STI make me immune to reinfection?

No. Successfully treating a bacterial STI (chlamydia, gonorrhea, syphilis) eliminates the current infection but confers no lasting immunity. Reinfection is common, which is why retesting at 3–6 months post-treatment is standard. This is especially relevant for syphilis — people who have been treated for it can and do get reinfected with subsequent exposures.

How do I find low-cost or free STI testing near me?

Federally Qualified Health Centers (FQHCs), Planned Parenthood locations, and state and local health department clinics provide free or sliding-scale STI testing. The CDC STI resources page includes links to testing locators. The USPSTF’s Grade B recommendation for chlamydia and gonorrhea screening in women under 25 means most insurance plans — including Medicaid — must cover this screening without cost-sharing.

Should both partners be treated at the same time?

Yes. Simultaneous treatment of all sexual partners is essential to prevent the ping-pong effect of reinfection. Expedited Partner Therapy (EPT) — the provision of medication or a prescription to a partner without requiring them to visit a clinic — is endorsed by the CDC and legal in most states. It is particularly effective for reducing chlamydia and gonorrhea reinfection rates.

How does gonorrhea antibiotic resistance affect my treatment?

Significantly. Because roughly half of all gonorrhea infections are resistant to at least one antibiotic, and because treatment options have narrowed considerably over the past two decades, ceftriaxone (injected, not oral) is now the only recommended first-line treatment for gonorrhea in the CDC’s 2021 guidelines. The USPSTF explicitly advises clinicians to consult the most current CDC guidance because treatment recommendations for gonorrhea can change as resistance patterns evolve. If your symptoms persist after treatment, return to your provider for a culture with sensitivity testing.

Take Action: Your Next Steps After Reading This Guide

Knowledge without action changes nothing. If you have not been tested recently and recognize yourself in any of the risk criteria described above, book an appointment this week — with your primary care provider, a community health clinic, or through an at-home testing kit if access is a barrier. If you are symptomatic, go to a clinical provider: at-home tests do not replace the examination, treatment prescription, and co-infection screening that a symptomatic visit provides.

If you receive a positive diagnosis, complete the full treatment course as prescribed. Do not stop antibiotics early because symptoms resolve — the course length exists for microbiological reasons, not symptom management. Notify your partners. Retest at the intervals specified for your particular infection. And understand that a positive STI result is a clinical event, not a moral verdict — it is information that gives you the ability to protect your health and your partners’ health.

For viral STIs including HIV and herpes, the goal shifts from cure to management. Connect with a provider who can discuss suppressive therapy options, transmission reduction strategies, and monitoring schedules. For HIV specifically, starting antiretroviral therapy promptly after diagnosis is associated with better long-term outcomes and eliminates sexual transmission risk when an undetectable viral load is achieved and maintained.

Finally, bookmark the CDC STI Treatment Guidelines and the USPSTF Screening Recommendations — both are updated as new evidence emerges, and both are free to access. Treatment guidelines are living documents in this field, particularly for gonorrhea, where resistance patterns shift and the Bicillin L-A shortage has already required real-time clinical adaptation in 2026. Staying current with authoritative sources is part of responsible sexual health management — for both patients and providers.

Sexual health, like immune system health more broadly, is maintained through consistent, informed habits — not crisis response. Testing is that habit. Treatment is the correction. Follow-up is the confirmation. All three together are what this guide is built for.

Medical Disclaimer: This article is intended for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Treatment dosages, screening intervals, and clinical recommendations referenced in this article are based on CDC 2021 STI Treatment Guidelines, USPSTF recommendations, and other public health sources current at the time of writing; guidelines may change as new evidence emerges. Always consult a qualified healthcare provider for individualized medical guidance, diagnosis, and treatment decisions. If you believe you may have been exposed to an STI or are experiencing symptoms, seek prompt evaluation from a licensed medical professional.